Search clinical trials for: Guselkumab Subcutaneous

Total 801 results

Janssen Research & Development, LLC

Recruiting

A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR Jr)

Colitis, Ulcerative

Belgium, United States, China, Denmark, Japan, Italy, Turkey, Poland
Janssen Research & Development, LLC

Active, not recruiting

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease (GALAXI)

Crohn's Disease

United States, Israel, Japan, Belgium, Lebanon, Taiwan, Netherlands, Russian Federation, Korea, Republic of, Jordan, France, Portugal, Turkey, Greece, Canada, Germany, Malaysia, Belarus, Latvia, Poland, Australia, Italy, Croatia, China, United Kingdom and more
Janssen Research & Development, LLC

Withdrawn

A Study of Guselkumab in Adult Participants With Celiac Disease

Celiac Disease

United States
University of California, San Francisco
Janssen Scientific Affairs, LLC

Recruiting

Immune Spatial Features of Guselkumab Cutaneous Response

Psoriasis of Scalp

United States
University of California, San Francisco
Janssen Biotech, Inc.

Recruiting

Guselkumab Immunogenetics (TIG)

Plaque Psoriasis | Psoriasis Guttate

United States
Janssen-Cilag Ltd.

Terminated

Effect of Guselkumab on Cardiovascular Risk Surrogate Markers in Participants With Moderate to Severe Plaque Psoriasis (G-CARE)

Psoriasis

Italy, Germany, Greece
Janssen Research & Development, LLC

No longer available

Post-Trial Access for Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli
Janssen Research & Development, LLC

Completed

A Study to Characterize the Elimination of Guselkumab Glycoform Variants in Healthy Participants

Healthy

United States
University Medical Center Groningen
Janssen-Cilag Ltd.

Completed

Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (HiGUS)

Hidradenitis Suppurativa

Netherlands
Janssen-Cilag S.p.A.

Completed

A Study of Guselkumab in Naive or Bio-experienced Participants With Regional (Facial and Genital) Psoriasis (GULLIVER)

Psoriasis

Italy
NYU Langone Health
Janssen Scientific Affairs, LLC

Recruiting

Multi-Center PAMPA Study (PAMPA)

Psoriasis

United States, Canada
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Crohns Disease

Japan
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis (QUASAR)

Ulcerative Colitis

United States, Belgium, Netherlands, Japan, United Kingdom, France, Korea, Republic of, Taiwan, Jordan, Turkey, Canada, Israel, Germany, Malaysia, Hungary, Ireland, Latvia, Bulgaria, Poland, Australia, Italy, China, Spain, Czechia, Russian... and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) (NOVA)

Hidradenitis Suppurativa

United States, France, Canada, Germany, Netherlands, Denmark
Stealth BioTherapeutics Inc.

Completed

ReCLAIM-2 Study to Evaluate Safety,Efficacy & Pharmacokinetics of Elamipretide in Subjects With AMD With Non-central GA (ReCLAIM-2)

Age-related Macular Degeneration

United States
Janssen-Cilag Ltd.

Recruiting

Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients (REASON)

Crohn's Disease

Taiwan, Israel
Janssen Research & Development, LLC

Completed

A Study of Subcutaneously-administered Guselkumab Delivered by 3 Different Devices in Healthy Participants

Healthy

United States, Germany
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of CNTO1959 (Guselkumab) in the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Pustular Psoriasis

Japan
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetic Comparability of Guselkumab (CNTO1959) When Delivered by 2 Different Devices and as 2 Formulations in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Completed

A Study of Guselkumab (TREMFYA) in Chinese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

China
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab for the Treatment of Participants With Crohn's Disease After Surgical Resection (PROGRESS)

Crohn's Disease

United States, Poland
Janssen Research & Development, LLC

Completed

A Study of Guselkumab in Participants With Familial Adenomatous Polyposis

Adenomatous Polyposis Coli

United States, Germany, France, Israel, Netherlands, Poland, Puerto Rico, Spain, Sweden
University of California, San Diego

Recruiting

Guselkumab (Anti-IL 23 Monoclonal Antibody) for Alcohol Associated Liver Disease

Alcoholic Liver Disease

United States
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis (ASTRO)

Colitis, Ulcerative

France, United States, Jordan, Taiwan, Turkey, Canada, Germany, Malaysia, New Zealand, Korea, Republic of, Hungary, Poland, Australia, Belgium, Japan, China, Czechia, Israel, India, Brazil, Spain, Argentina, Slovakia, Bulgaria, Mexico
Janssen Research & Development, LLC

Active, not recruiting

A Study of Guselkumab Subcutaneous Therapy in Participants With Moderately to Severely Active Crohn's Disease (GRAVITI)

Crohn Disease

Belgium, United States, Japan, Czechia, Hungary, Korea, Republic of, France, Taiwan, Germany, Malaysia, New Zealand, Poland, Canada, Turkey, Croatia, Israel, China, Denmark, Netherlands, Brazil, Italy, Spain, Jordan, Bosnia and Herzegovina and more
Janssen Research & Development, LLC

Active, not recruiting

A Study to Evaluate Guselkumab for the Treatment of Participants With New-onset or Relapsing Giant Cell Arteritis (THEIA)

Giant Cell Arteritis

United States, Canada, Belgium, Israel, Italy, Germany, France, Spain, Poland
Rockefeller University
Janssen Scientific Affairs, LLC

Withdrawn

Biomarkers in Participants With Hidradenitis Suppurativa Receiving Guselkumab.

Hidradenitis Suppurativa

United States
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Safety, Tolerability and Pharmacokinetics of Guselkumab Following a Single Intravenous Administration in Healthy Japanese Participants

Healthy

Japan
Janssen Research & Development, LLC

Active, not recruiting

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis (VISIBLE)

Plaque Psoriasis | Scalp Psoriasis

United States, Canada
Janssen Pharmaceutica N.V., Belgium

Recruiting

A Study of Guselkumab and Interleukin-17 (IL-17) Inhibitor Therapies in Participants With Psoriatic Arthritis in Routine Clinical Practice (PsABIOnd)

Arthritis, Psoriatic

Belgium, Korea, Republic of, Austria, Germany, Japan, Mexico, Greece, United Kingdom, Italy, Sweden, Spain, France, Taiwan, Netherlands, Canada, Argentina, Australia, Colombia, Russian Federation, Switzerland
Janssen-Cilag International NV

Active, not recruiting

A Study to Evaluate Further Therapeutic Strategies With Guselkumab in Participants With Moderate-to-Severe Plaque-Type Psoriasis (GUIDE)

Psoriasis

Germany, France
Janssen Research & Development, LLC

Terminated

A Study of Guselkumab and Risankizumab in Healthy Participants and Participants With Psoriatic Arthritis

Healthy | Arthritis, Psoriatic

Austria
Janssen-Cilag Ltd.

Completed

A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis (G-PLUS)

Psoriasis

Germany, France, Italy, Spain, United Kingdom
Janssen Research & Development, LLC

Completed

Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants

Healthy

China
Janssen Research & Development, LLC

Completed

A Study of Intravenous Formulation of Guselkumab Using Prefilled Syringes and Final Vialed Product in Healthy Participants

Healthy

Germany
Beijing Friendship Hospital

Unknown

ESM Versus OM ：A Randomized Controlled Trial

Endoscopic Subcutaneous Mastectomy

China
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Systemic Sclerosis

Scleroderma, Systemic

Japan
Oregon Health and Science University

Active, not recruiting

Guselkumab in the Treatment of Pityriasis Rubra Pilaris (PRP)

Pityriasis Rubra Pilaris

United States
Centre for Human Drug Research, Netherlands
Janssen Pharmaceuticals

Recruiting

An Explorative Psoriasis Biomarker Study

Psoriasis Vulgaris

Netherlands
University Hospitals Cleveland Medical Center
Case Western Reserve University; LEO Foundation

Recruiting

Development of Predictive Psoriasis Response Endotypes Using Single Cell Transcriptomics

Psoriasis

United States
Regado Biosciences, Inc.

Completed

Safety, Tolerability and PK/PD of RB006 in a Healthy Volunteer SAD (SC101)

Healthy Volunteer

United States
Astellas Pharma Europe B.V.

Completed

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

Healthy Subjects | Pharmacokinetics of ASP6294

United Kingdom
The University of The West Indies

Not yet recruiting

To Investigate the Effect of Continuous Versus Interrupted Subcutaneous Fat Closure in Reducing Surgical Site Infection Among Over-weight or Obese Women Who Are Undergoing Elective Caesarean Section

Overweight or Obese Women, Elective Lower Segment Cesarean Section
Eli Lilly and Company

Completed

A Study of LY3016859 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Ain Shams University

Completed

Closure Versus Non Closure of Subcutaneous Tissue After Cesarean Section in Diabetic Patients

Abdominal Delivery
AlRefaey Kandeel

Completed

Subcutaneous NTG for US Radial Artery Cannulation (NTG-US-art)

Morbid Obesity
Menoufia University

Completed

Subcutaneous Drains And Cesarean Section

Cesarean Section

Egypt
University Hospital, Limoges

Terminated

Oedematous Lower Limb Subcutaneous Drainage in Palliative Care (DSOPAL)

Edema

France
Boston Scientific Corporation

Completed

ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients

Heart Failure | Long QT Syndrome | Wide QRS Complexes | Cardiac Resynchronisation

United Kingdom
Novartis Pharmaceuticals

Completed

Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD)

Treatment-Resistant Depression

Spain, Japan, Poland, United States

Search clinical trials for: Guselkumab Subcutaneous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations